[{"id":"eced6ff3-eb59-4479-abc1-1ecf256e2ffb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05445310","created_at":"2022-07-06T15:54:35.837Z","updated_at":"2024-07-02T16:35:55.397Z","phase":"Phase 2","brief_title":"Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05445310","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L858R + EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L858R + EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 08/06/2022","start_date":" 08/06/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-02-16"}]